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Introduction 
 Heart disease is known to be the leading cause of death in both men and women in the 
United States.  Coronary disease accounts for over 108 billion dollars spent, including health 
services provided, medications, and productivity lost (Centers for Disease Control and 
Prevention, 2015).  Acute coronary syndrome (ACS) results from atherosclerotic plaques that 
line the walls of coronary arteries resulting in myocardial ischemia or infarction and account for 
more than 700,000 hospital admissions in this country every year (Keifer & Becker, 2009).  
When these plaques rupture, macrophages and pre-inflammatory mediators are released in the 
blood, causing activation of the clotting cascade and subsequent thrombus formation (Wright & 
Antoniou, 2013).   
Stenting or coronary artery bypass grafting is the standard of care for repairing 
atherosclerotic lesions.  When stenting is used, it is imperative to initiate dual antiplatelet therapy 
after percutaneous coronary intervention (PCI) for the prevention of stent thrombosis and 
increased mortality (Mrdovic et al., 2013).  Clopidogrel, a thienopyridine, along with aspirin 
have previously been the drugs of choice for the treatment of ACS and to prevent stent 
thrombosis.  However, the drug has drawbacks.  Clopidogrel has a delayed onset of action, 
taking two to four hours after a six hundred milligram loading dose to achieve platelet inhibition 
(Wright & Antoniou, 2013).  Clopidogrel is a drug that is metabolized through the hepatic 
cytochrome P450 pathway, therefore making it susceptible to genetic polymorphisms and drug 
interactions (Roffman, 2010).   
The limitations of colpidogrel have brought about newer, more potent antiplatelet drugs.  
Prasugrel, another thienopyridine, has an advanced onset of action, causing platelet reactivity in 
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15 to 30 minutes (Wright & Antoniou, 2013).  Ticagrelor is another P2Y12 inhibitor that is taken 
twice a day.  However, it does not metabolize in the liver, and it reversibly bonds to platelets 
(Wright & Antoniou, 2013).  These new antiplatelet drugs, being more potent, carry a higher risk 
of bleeding.  With the variety of antiplatelet drugs available, the question must be asked which 
drug should be the drug of choice for patients after PCI.  The purpose of this literature review is 
to investigate various research and identify which antiplatelet therapies will be more beneficial 
for specific patient groups so that medical therapy can be optimized after stent implantation. 
Method 
Search for this review was limited to articles from 2001 through 2015 using CINAHL, 
MEDLINE, and the Cochrane Library.  The following search words were used: antiplatelet, 
antiplatelet therapy, stent thrombosis, clopidogrel, prasugrel, and ticagrelor.   
Clopidogrel 
   Several studies were reviewed that were clopidogrel specific.  One trial focused on the 
effects of clopidogrel and aspirin, and four trials focused on the duration and dose of clopidogrel 
and aspirin.  In the CURE trial, a randomized, double-blind, placebo-controlled study 
investigated clopidogrel compared with placebo in acute coronary syndrome patients without 
ST-segment elevation (Yusuf et al., 2001).  Patients in this study were randomized and given a 
loading dose of clopidogrel (300 mg orally) or a placebo followed by a daily dose of clopidogrel 
(75 mg orally) or a placebo for three to twelve months.  An aspirin daily dose of 75 to 325 
milligrams was also given during the duration of the study.  In this study, clopidogrel along with 
aspirin was shown to significantly lower the risk of myocardial infarction and ischemia.  The 
drug, however, was associated with an increased risk of bleeding.  
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The GRAVITAS trial evaluated the effects of high dose clopidogrel (600 mg loading 
dose followed by 150 mg daily dose thereafter) and standard dose clopidogrel (300 mg standard 
loading dose followed by 75mg daily dose thereafter).  This randomized, double-blind, active-
control trial measured the responsiveness of platelet reactivity at 12 and 24 hours after the 
completion of PCI with drug eluding stents (DES) with the VerifyNow assay (Price et al., 2011).  
The VerifyNow assay is a test used to measure the level of platelet P2Y12 receptor blockade so 
that high residual platelet reactivity (HRPR), also known as poor responders to clopidogrel, can 
be identified to help reduce the risk of an adverse cardiovascular event (Accumetrics, 2015).  
The study concluded that high dose clopidogrel in patients with HRPR only gave a modest 
reduction in platelet reactivity when compared with standard dose clopidogrel, but the higher 
dose of clopidogrel did not prove to reduce the rate of death from cardiovascular events (Price et 
al., 2011).   
Three other research studies investigated the optimal duration of clopidogrel.  The DES 
LATE trial was designed to evaluate the hypothesis that 12 month dual antiplatelet therapy with 
clopidogrel and aspirin was just as effective as therapy that was extended past 12 months.  The 
trial proved that an additional 24 months of antiplatelet therapy with clopidogrel compared with 
aspirin alone did not lower the end point of death from cardiac causes (Lee et al., 2013).  
Research done by Sardella et al. (2012) compared 12 month dual antiplatelet therapy after DES 
implantation versus prolonged therapy (less than twelve months) after DES implantation.  The 
results of the study showed that prolonged therapy, based on physician preference, reduced the 
rate of major adverse cerebro-cardiovascular events (MACCE) in patients on dual antiplatelet 
therapy receiving DES implantation.  However, a study conducted by Poorhosseini et al. (2012) 
investigated dual antiplatelet therapy for the prevention of stent thrombosis in patients 
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undergoing PCI with DES implantation. The study showed that extended therapy was not 
significantly more effective than aspirin alone in the prevention of death from cardiovascular 
causes (stent thrombosis or myocardial infarction). 
Clopidogrel’s antiplatelet effect is highly variable, and the pharmacokinetics and 
pharmacodynamics along with known factors were examined in a study by Frelinger et al., 
(2013).  In this study, patients were confined to the research unit for 10 days while their diet, 
fluid, and activity were controlled, and a genotype analysis was performed.  The study showed 
that pharmacokinetics and pharmacodynamics varied widely despite control of diet, nicotine, and 
medications (including proton pump inhibitors and statins), and identifiable factors only 
accounted for less than around 18 percent of a variation in clopidogrel (Frelinger et al., 2013).  
Measured platelet reactivity accounted for 35 to 65 percent of the variation. However, the 
remaining variations are unclear (Frelinger et al., 2013).     
Prasugrel 
Prasugrel is a third generation thienopyridine that is more potent, is not affected by the 
CYP2C19 polymorphism like clopidogrel, and has a more rapid onset of action.  The TRITON-
TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet 
Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction) showed that prasugrel versus 
clopidogrel significantly reduced the rate of ischemic events in patients having PCI (Wiviott et 
al., 2007).  In this study, in a double-blind manner, patients were given loading doses of 
prasugrel or clopidogrel after PCI, followed by daily maintenance doses of the assigned drug.  
Data showed that prasugrel had a more rapid onset of action, where platelet inhibition was 
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achieved within 30 minutes after the drug was given with a similar peak effect as clopidogrel at 
six hours.   
In a substudy of the TRITON-TIMI 38 trial, Salisbury et al. (2012) developed risk 
prediction models for major ischemic complications and bleeding after PCI as a treatment plan 
with clopidogrel and prasugrel.  These prediction models can be implemented at the time of PCI 
to determine the risk of complications associated with treatment of prasugrel and clopidogrel 
(Salisbury et al., 2013).  This model can assist clinicians in assessing patients’ risks for each 
decision made in the treatment of ACS.  The study determined that multivariable risk models can 
help to identify patient’s risk of adverse events after PCI and allow antiplatelet therapy to be 
tailored based on the risk profile of each patient.  For example, a young diabetic male has an 11.4 
percent reduction of ischemia risk if taking prasugrel, however a 66 year old female presenting 
with ST-elevation has a higher risk of bleeding on prasugrel and would benefit from clopidogrel.   
 Since prasugrel is more potent, the risk of bleeding increases when compared to 
clopidogrel.  Patients that are low body weight (<60 kg) are at an even greater risk for bleeding.  
Therefore, the FEATHER trial was designed to evaluate previous data that suggested that low 
dose prasugrel (5 mg) in low body weight (LBW) patients was equivalent to standard dose 
prasugrel (10 mg) in higher body weight (HBW) patients (Erlinge et al., 2012). The study 
showed that LBW patients had a higher occurrence of treatment-related bleeding than HBW 
patients, however, the bleeding events were minor and not significant.  Laboratory data proved 
that platelet inhibition was not compromised in LBW patients receiving lower dose prasugrel, in 
fact, the maintenance dose of 5 mg in LBW patients resulted in similar high on-treatment platelet 
(HTPR) reactivity as HBW patients taking 10 mg maintenance dose of prasugrel.     
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Ticagrelor 
 Ticagrelor is a drug that falls into a new class of P2Y12 inhibitors called cyclopentyl-
triazolo-pyrimidine (CPTP) and binds to platelets reversibly (Wright & Antoniou, 2013).  The 
PLATO study was developed to evaluate whether ticagrelor was superior to clopidogrel in acute 
coronary syndrome.  Results showed that ticagrelor significantly reduced the rate of death from 
vascular causes, myocardial infarction, and stroke when compared to clopidogrel without greatly 
increasing the rate of major bleeding (Wallentin et al., 2009).  Patients receiving stents during the 
study also showed a lower incidence of stent thrombosis in the ticagrelor group.  Patients in the 
ticagrelor group experienced more episodes of dyspnea than the clopidogrel group, however, 
most instances lasted less than a week.   
 In an analysis from the PLATO trial, Steg et al. (2013) sought to examine the effects of 
ticagrelor on stent thrombosis in patients from the PLATO trial having PCI.  The observation 
showed that 147 patients in PLATO had definite stent thrombosis with the majority being men, 
smokers, those with previous cardiovascular disease, and diabetics. Patients were randomly 
assigned to a study drug, and the drug was given prior to PCI.  Most of the stent thrombosis 
cases occurred within the first thirty days after PCI.  There was no statistical difference between 
ticagrelor and clopidogrel in acute stent thrombosis (the first 24 hours after PCI), but ticagrelor 
was shown to reduce the incidence of stent thrombosis in patients within the first 30 days of PCI.   
 The RESPOND study was aimed at investigating the antiplatelet effects of ticagrelor 
(dosed according to the PLATO trial) and platelet function when switching patients from 
7 
OPTIMIZING ANTIPLATELET THERAPY IN ACS AFTER PCI 
clopidogrel to ticagrelor and vice versa (Gurbel et al., 2010).  To assess clopidogrel 
responsiveness, patients were given 300 mg clopidogrel, and platelet aggregation was assessed at 
six and eight hours after dosing.  The study showed that ticagrelor has greater platelet inhibition 
on those who are on clopidogrel and that ticagrelor overcame clopidogrel nonresponsiveness.  
When therapy was switched, ticagrelor was shown to have rapid platelet inhibition, but when 
switching to clopidogrel patients were shown to have a reduction in platelet inhibition.  
Ticagrelor was also shown to be highly effective in lowering the HTPR, proving that patients 
benefit from ticagrelor therapy.   
 Wallentin et al. (2013) conducted a substudy from the PLATO trial by identifying 
biomarkers that might identify different patient groups with different effects of ticagrelor 
compared to clopidogrel.  The study observed these biomarkers: high-sensitivity troponin T hs-
TnT), N-terminal probrain natriuretic peptide (NT-proBNP), and growth differentiation factor-15 
(GDF-15) in treatment.  Patients that were found to have elevated levels of hs-TnT showed a 
benefit of having ticagrelor over clopidogrel.  The study found that the benefit of ticagrelor is 
correlated to the elevation of GDF-15 and NT-proBNP.  With this information, treatment may be 
tailored to patients.         
 The ONSET/OFFSET study compared the onset and offset of platelet inhibition in 
patients using 180 mg loading dose of ticagrelor and the 600 mg loading dose of clopidogrel 
(Gurbel et al., 2009). This study showed that ticagrelor has a more rapid onset (observed effect 
within 30 minutes of loading) of antiplatelet effect than high dose clopidogrel.  The antiplatelet 
effect was greater and better maintained for the duration of therapy with ticagrelor than with 
clopidogrel, and the offset of the drug occurred much more rapidly with ticagrelor than with 
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clopidogrel.  Data was also given that bleeding risk was less in patients when therapy was 
terminated 48 to 120 before surgery.   
Prasugrel vs Ticagrelor 
 Two studies investigated the newer antiplatelet drugs.  In ST-elevation myocardial 
infarction (STEMI) patients, rapid platelet effect is imperative, so the RAPID primary PCI study 
was conducted to compare prasugrel and ticagrelor in STEMI patients (Parodi et al., 2013).  
Results showed that prasugrel was noninferior to ticagrelor two hours after the loading dose, but 
it took four hours to achieve a sufficient drug effect.  Morphine delayed the action of prasugrel 
and ticagrelor.   
 Diabetic patients tend to have increased platelet reactivity and are usually found to be less 
responsive to clopidogrel (Alexopoulos et al., 2013).  Alexopoulos et al. (2013) set out to 
evaluate the antiplatelet effect of prasugrel and ticagrelor in patients with diabetes mellitus.  
VerifyNow testing was used to show that ticagrelor gave patients a stronger platelet inhibition 
but prasugrel and ticagrelor showed an adequate treatment of HPR.   
Tailoring Antiplatelet Therapy 
 Dual antiplatelet therapy is the treatment of choice for patients with acute coronary 
syndrome that have undergone PCI.  Several studies were investigated to determine if tailored 
therapy is beneficial to patients and whether or not it is cost effective.  Since hyporesponsiveness 
to clopidogrel after drug-eluding stent placement is predictor of stent thrombosis, research was 
conducted by Sharma et al. (2013) to investigate the use of platelet function testing to predict 
hyporesponsiveness to clopidogrel when patients present with chest pain to the emergency 
department.  Based on platelet function assays, this study determined that diabetics and African 
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Americans were more likely to be platelet reactive and less likely to be respondent to antiplatelet 
therapy.  The study concluded that patients presenting with chest pain who are currently taking 
clopidogrel may benefit from platelet function testing to screen for hyporesponders and 
nonresponders as well as identify medication noncompliance. 
 Tailored antiplatelet therapy in patients may be a better alternative to standard therapy 
with clopidogrel and aspirin after stent implantation. A large number of the population seem to 
have HTPR, and experience adverse events due to stent thrombosis (Li et al., 2013).  Antiplatelet 
resistant patients were shown to have a reduced rate of stent thrombosis and death when their 
therapy was personalized.  The study also found that patients with tailored therapy did not have 
an increased risk of bleeding when compared to conventional therapy in resistant patients.    
 The cost effectiveness of genotype-guided therapy was reviewed in two studies 
investigated.  Patel et al. (2014) determined that clopidogrel was less costly and was less 
effective when compared to prasugrel and genotype-guided therapy.  Clopidogrel was found to 
be cheaper but may not be appropriate due to drug interactions, genetic polymorphisms, and 
delayed onset of action.  It was determined that genotyping therapy is cost effective when 
compared with clopidogrel and prasugrel, but when genotype therapy is not available, 
clopidogrel is less costly.  Patient characteristics and economic conditions should be considered 
when selecting antiplatelet therapy (Patel et al., 2014).  Kazi et al. (2014) evaluated the cost-
effectiveness of genotype-guided therapy after stent implantation in ACS patients where 
clopidogrel, prasugrel, and ticagrelor along with genotype-guided strategies were used.  Direct 
medical costs (inpatient admissions, procedures, outpatient visits, and drugs) and cost associated 
with complications, loss of wages and caregiver costs were assessed when determining cost-
effectiveness.  They confirmed that genotyping patients with CYP2C19 alleles and those that are 
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clopidogrel non-responders is an economically attractive option, but treating all patients with 
ticagrelor may be a better alternative and economically reasonable.    
Results 
 Aspirin and clopidogrel are accepted as the regimen of choice in patients with acute 
coronary syndrome after PCI.  The CURE trial showed that clopidogrel, along with aspirin, 
significantly reduces the risk of death from cardiovascular causes (Yusuf et al., 2001).  
Treatment with high dose clopidogrel (600 mg loading dose and 150 mg thereafter) in patients 
with HTPR is not necessary.  The GRAVITAS trial proved that standard dose clopidogrel (300 
mg loading dose and 75 mg thereafter) was equal to high dose clopidogrel, and high dosing did 
not reduce the incidence of death from cardiovascular events, myocardial infarction, or stent 
thrombosis (Price et al., 2011).  Prolonging therapy with clopidogrel and aspirin for longer than 
twelve months did not significantly reduce adverse cardiac events and may increase the risk for 
bleeding (Lee et al., 2013; Poorhosseini et al., 2012).  Various factors contribute to the variability 
of platelet inhibition with clopidogrel and despite controlling diet, medication compliance, 
nicotine, the pharmacokinetics and pharmacodynamics still had significant differences 
(Freelinger et al., 2013). 
   The TRITON-TIMI 38 trial was designed to compare prasugrel and clopidogrel in 
patients with acute coronary syndrome.  Wiviott et al. (2007) proved that prasugrel was better at 
reducing the rates of stent thrombosis when compared to clopidogrel but it increased bleeding 
rates.  The FEATHER trial showed that prasugrel dosing should be reduced in patients under 60 
kilograms (from 10 mg daily to 5 mg daily) to reduce bleeding in low body weight patients.  
Evidence shows that this does not reduce the amount of platelet inhibition (Erlinge et al., 2012).  
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It should also be noted that the use of prasugrel is contraindicated in patients with a history of 
previous stroke or TIAs and is not recommended for patients over the age of 65 years of age.   
 Ticagrelor is a new non-thienopyridine drug that is reversible and provides faster platelet 
inhibition.  The PLATO study compared clopidogrel with ticagrelor and showed that ticagrelor 
significantly reduced the risk of cardiac events and death from vascular causes when compared 
to clopidogrel but did increase the incidence of bleeding (Wallentin et al., 2009).  Storey et al. 
(2013) pinpointed stent thrombosis, showing that ticagrelor reduced the incidence of stent 
thrombosis in ACS patients following PCI when compared to clopidogrel.  A substudy from the 
PLATO trial by Wallentin et al. (2014) determined that hs-TnT, NT-proBNP, and GDF-15 can 
be predictors of adverse cardiac events such as cardiovascular death, myocardial infarction, and 
stroke.  The RESPOND study showed that ticagrelor overcomes clopidogrel nonresponsiveness 
and has a better antiplatelet effect in patients previously treated with clopidogrel that are 
switched to ticagrelor (Gurbel et al., 2010).  The ONSET/OFFSET trial proved that ticagrelor 
has a faster antiplatelet effect than clopidogrel and a shorter duration after discontinuation 
(Gurbel et al., 2009).   
 Both prasugrel and ticagrelor are new generation antiplatelet drugs that have proved to be 
superior to clopidogrel.  The RAPID PCI study tested the effects of prasugrel and ticagrelor, and 
both drugs proved to be equal in platelet reactivity.  Both drugs showed that they needed at least 
four hours for optimal effect in ST-elevated patients (Parodi et al., 2013).  Alexopoulos et al. 
(2013) found that both prasugrel and ticagrelor provided adequate platelet inhibition in HPR 
patients, but ticagrelor achieved a much greater platelet inhibition in diabetic patients that had 
previously been treated with clopidogrel and had previously undergone stent implantation.   
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 There is a large percentage of the population that does not respond to platelet inhibition 
from clopidogrel.  Nonresponders are more likely to be African American and diabetic (Sharma 
et al., 2013).  Tailored antiplatelet therapy has proven to be associated with a reduced rate of 
stent thrombosis and adverse events without adversely effecting bleeding risks (Li et al., 2014).  
Genotype-guided antiplatelet therapy has shown to be cost-effective and may improve the cost 
effectiveness of prasugrel and ticagrelor (Patel et al., 2014; Kazi et al., 2014).  However, 
ticagrelor across the board may be a more cost effect treatment for ACS patients undergoing PCI 
(Kazi et al., 2014). 
Conclusion 
 Clopidogrel is an acceptable and proven strategy for preventing stent thrombosis in 
patients with ACS receiving PCI and continue to be used as a cost effective treatment.  However, 
the new generation antiplatelet agents prasugrel and ticagrelor have shown to be more potent and 
produce a more rapid onset of platelet inhibition, especially in individuals with the reduced 
function allele CYPC19, in African Americans, and in those with diabetes mellitus.  Tailored 
antiplatelet therapy is a cost-effective way to optimize outcomes and reduce adverse cardiac 
events.  Ticagrelor is a more superior option because of its reversibility and faster onset of 
action, but the twice a day dosing may cause noncompliance.   
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